Inhibiting CXCR2 has been used to preclude neutrophil recruitment to tissues, and, currently, several clinical trials are investigating the safety and efficacy of small molecule inhibitors and antibodies targeting CXCR2 in combination with ICIs or radiotherapy in several types of cancer, including HNSCC, PDAC, metastatic castrate-resistant prostate cancer, hormone-sensitive prostate cancer, HCC, NSCLC, and metastatic melanoma [206]. The gene discussed is CXCR2; the disease is cancer.